PDL192 is a humanized monoclonal antibody that binds to the TWEAK (tumor necrosis factor-like weak inducer of apoptosis) receptor (TweakR), a cell surface glycoprotein with homology to the family of tumor necrosis factor (TNF) receptors.

PDL192 appears to have dual mechanisms of action, where binding to the target results in a biological signal detrimental to the cancer cell. In addition, PDL192 may be able to recruit the immune system to mediate antibody-dependent cellular cytotoxicity (ADCC) activity to help destroy the tumor. TweakR appears to be over-expressed in a number of solid tumor indications including pancreatic, colon, lung, renal, breast and head and neck cancers, and ongoing scientific work will help prioritize those tumors for therapeutic testing. In preclinical studies, PDL192 also has been shown to inhibit tumor growth of various models of human cancer in mice.

PDL192 is currently in clinical development for solid tumors. We own the worldwide rights to PDL192.

Please visit our PDL192 publications page to view our most recent data presentations for this program.

For inquiries about our clinical trials, please call our information line at 650 454-1400 or visit the National Institutes of Health website (http://www.clinicaltrials.gov).